1. Introduction {#sec1-jcm-09-00149}
===============

Blood glucose level can be transiently elevated because of stress response to acute illness, so-called stress hyperglycemia (HGL). There is a growing body of evidence that admission HGL affects short- and long-term clinical outcomes in patients with acute myocardial infarction (AMI), regardless of the patients' status of diabetes mellitus (DM) \[[@B1-jcm-09-00149],[@B2-jcm-09-00149],[@B3-jcm-09-00149],[@B4-jcm-09-00149]\]. Microvascular dysfunction, proinflammatory status, and prothrombotic status in AMI patients with admission HGL might be possible explanations for these poor clinical outcomes. However, there is a paucity of data regarding the impact of admission HGL on clinical outcomes in acute heart failure (AHF).

Activation of the sympathetic nervous system (SNS) is one of major neuro-hormonal mechanism of the development or progression of HF. Decreased cardiac output activates SNS and thereby promotes myocyte hypertrophy and fibrosis, and in turn impairs diastolic and systolic function of both ventricles \[[@B5-jcm-09-00149]\]. Activation of the SNS also causes inhibition of glucose-stimulated insulin secretion via the α-receptor. Pathological stress states may induce a metabolic state similar to diabetes with HGL and poor insulin responses to glucose challenge \[[@B6-jcm-09-00149]\]. For these reasons, admission HGL can develop and reflect the degree or status of SNS activation in patients with AHF. If the higher admission glucose can reflect the higher SNS activation, therefore, it is presumed that admission HGL might be associated with clinical outcomes in patients with AHF. Actually, the study of Kattel S et al. \[[@B7-jcm-09-00149]\] demonstrated that increased blood glucose level is a predictor of long-term mortality in patients with acute decompensated HF, irrespective of the DM status. Furthermore, in a study of 5428 previously non-DM patients with AHF, admission HGL was associated with higher in-hospital mortality than in AHF patients without admission HGL \[[@B8-jcm-09-00149]\]. Contrary to results of these studies, however, admission glucose level was not a predictor of mortality a large cohort study of elderly HF patients \[[@B9-jcm-09-00149]\]. Therefore, the association between admission glucose level and HF mortality should be clarified through larger studies.

The aim of this study, therefore, was to investigate the impact of admission HGL on clinical outcomes including in-hospital and long-term mortality in AHF patients with or without DM by analyzing the data from the nationwide large AHF cohort registry.

2. Materials and Methods {#sec2-jcm-09-00149}
========================

2.1. Study Population {#sec2dot1-jcm-09-00149}
---------------------

A total of 5625 patients hospitalized for AHF from 10 tertiary university hospitals throughout the country were consecutively enrolled between March 2011 and February 2014 with a planned follow-up period through 2016. Patients who have signs or symptoms of HF and one of the following criteria are eligible for the study: (i) lung congestion or (ii) objective findings of left ventricular (LV) systolic dysfunction or structural heart disease. Lung congestion has been defined as 'congestion' on a chest X-ray or as rales on physical examination. There are no exclusion criteria. The patients were classified into de novo (new-onset AHF in a patient without previously known cardiac dysfunction), acute decompensation of chronic HF, or five clinical profiles (acute decompensated HF, hypertensive HF, pulmonary edema, cardiogenic shock, and right HF) by the attending physician according to the 2005 European Society of Cardiology (ESC) guidelines \[[@B10-jcm-09-00149]\]. The class of high-output HF was not recorded. The study protocol was approved by the ethics committee at each participating center, including Chonnam National University Hospital Institutional Review Board (project identification code: CNUH-2011-061). The present study was conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent for participation in the registry.

A total of 5625 cohort patients enrolled in Korean Acute Heart Failure (KorAHF) Registry. Of them, 48 patients were eliminated because they had no initial glucose level. Only AHF patients without history of DM and Hb. ≤ 6.4% were considered as non-DM patients in this study. Study population were divided into two groups according to the presence of DM; DM group (*n* = 2125, 70.4 ± 11.4 years) vs. non-DM group (*n* = 3416, 67.3 ± 16.0 years). Patients in each group were further divided into two groups according to the presence of admission HGL (admission serum glucose level \> 200 mg/dL); HGL group (*n* = 248) vs. no HGL group (*n* = 3168) in non-DM; HGL group (*n* = 799) vs. no HGL group (*n* = 1326) in DM ([Figure 1](#jcm-09-00149-f001){ref-type="fig"}). In-hospital death (IHD) and 1-year death during clinical follow-up were compared. All-cause mortality between HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) were also compared in the presence or the absence of DM or HGL. HFrEF was defined as heart failure with initial ejection fraction of \<40%.

2.2. Data Collection {#sec2dot2-jcm-09-00149}
--------------------

Written informed consents were obtained from each patient. If patients were unable to give consent due to disease severity, informed consents were obtained from a relative or legal representative. The attending physician completed a web-based case report form in the Clinical Data Management System (iCReaT) from the Korea National Institute of Health (NIH) with the assistance of a clinical research co-ordinator. The detailed variables and values collected at baseline admission and case definition were described in elsewhere \[[@B11-jcm-09-00149],[@B12-jcm-09-00149]\]. If the patients admitted via an emergency room, the initial presentation and laboratory results at emergency room were included in the baseline data. After discharge, events including all-cause death, death from HF aggravation, and re-hospitalization for HF aggravation were recorded. The latest information on a patient's clinical manifestation, biochemistry, and medication is collected at the first re-visit in 30 days, and at 3, 6, 12, 24, 36, 48, and 60 months. The follow-up data were collected from the patients by the attending physician and stored in the web-based case report form. The outcome data for subjects who had not been followed up have been ascertained by a telephone interview. In addition, the outcome data for patients lost to follow-up were collected from the National Death Records.

2.3. Echocardiographic Measurements {#sec2dot3-jcm-09-00149}
-----------------------------------

Comprehensive echocardiographic studies including Doppler studies were performed according to the current recommendations of the American Society of Echocardiography. Left ventricular end-systolic and end-diastolic dimensions, interventricular septal and posterior wall thicknesses, and left atrial anteroposterior diameter were determined from two-dimensional images. EF was calculated using the conventional Teicholz's and biplane Simpson's method. Doppler echocardiograms were recorded on a strip chart recorder with a sweep speed of 100 mm/s. Early transmitral velocity (E wave) was measured using pulsed-wave Doppler from the apical four-chamber view, with the sample volume located at the tip of the mitral leaflets. Early diastolic (e'), late diastolic (a'), and systolic (s') velocities at the septal mitral annulus were obtained in this view with tissue Doppler imaging. The E wave deceleration time (DT) was measured as the time between the peak early diastolic velocity and the point at which the steepest deceleration slope was extrapolated to the zero line.

2.4. Statistical Analysis {#sec2dot4-jcm-09-00149}
-------------------------

Continuous variables with normal distributions are presented as mean ± standard deviation and were compared using the Student's *t*-test or Mann--Whitney *U* test when group distributions were skewed. Categorical variables were compared using the chi-square test or Fisher's exact test, where appropriate. The comparison of baseline characteristics and echocardiographic findings between different sports discipline was performed using one-way analysis of variance. Cox proportional hazard regression was used to determine the independent effect of HGL in non-DM patients on long-term clinical outcomes. Variables with *p* \< 0.1 on univariate regression analysis and clinically relevant variables were tested in the model. All statistical tests were two-tailed and *p* value \< 0.05 were considered significant. All analyses were performed using the Statistical Package for Social Sciences, version 21.0 (SPSS, PC version, Chicago, IL, USA).

3. Results {#sec3-jcm-09-00149}
==========

3.1. Baseline Characteristics {#sec3dot1-jcm-09-00149}
-----------------------------

Baseline characteristics are summarized in [Table 1](#jcm-09-00149-t001){ref-type="table"}. DM was noticed in 2135 patients (38.6%); known DM in 1961 patients (92.3%) vs. newly diagnosed DM in 164 patients (7.7%). Admission HGL was noticed in 1047 patients (18.9%); 799 patients in DM group (37.6%) vs. 248 patients in non-DM group (7.3%). The overall comparison between DM vs. non-DM group was described in [Supplementary Materials (Table S1)](#app1-jcm-09-00149){ref-type="app"}.

In DM group, admission HGL was associated with more female sex, higher prevalence of pulmonary congestion, lower body mass index, higher blood pressure, higher heart rate, higher previous history of HF, higher prevalence of dyslipidemia and atrial fibrillation, and higher level of hemoglobin A1C, and high sensitivity C-reactive protein as compared to no admission HGL.

In non-DM group, admission HGL was associated with older age, higher prevalence of pulmonary congestion, lower body mass index, higher blood pressure, higher heart rate, more frequent previous history of HF, higher prevalence of hypertension, dyslipidemia, ischemic heart disease, and atrial fibrillation as compared to no admission HGL.

3.2. Echocardiographic Findings {#sec3dot2-jcm-09-00149}
-------------------------------

Echocardiographic findings are summarized in [Table 2](#jcm-09-00149-t002){ref-type="table"}.

In DM group, although LV ejection fraction was not different, LV and left atrial dimension were significantly larger in admission HGL group than in no admission HGL group. The parameters of diastolic function and systolic pulmonary artery pressure were not different between admission HGL and no admission HGL group.

In non-DM group, as in DM group, LV and left atrial dimension were also significantly larger in admission HGL group than in no admission HGL group even though LV ejection fraction was not different. Among non-DM patients, in contrary to DM group, E velocity, and E/E' ratio were significantly higher in admission HGL group than in no admission HGL group.

3.3. Prescribed Medications {#sec3dot3-jcm-09-00149}
---------------------------

Angiotensin converting enzyme inhibitors or angiotensin receptor blockers were used similarly between the groups. However, beta-blockers were used more frequently used in diabetic patients with HGL than in those without HGL (59.1% vs. 50.5%, *p* \< 0.001). Furosemide was used less frequently in non-diabetic patients with HGL (71.4% vs. 62.9%, *p* = 0.004). Digoxin was used more frequently in patients without HGL (18.4% vs. 25.2%, *p* \< 0.001 in DM; 17.7% vs. 28.1%, *p* \< 0.001 in non-DM) because atrial fibrillation was more prevalent in this patient group. Aspirin and statin were used more frequently in patients with HGL (58.3% vs. 51.9%, *p* = 0.004 in DM; 44.4% vs. 32.4%, *p* \< 0.001 in non-DM)

### Impacts of DM and Admission HGL on IHD and 1-Year Death

IHD developed in 269 patients (4.9%), and 1-year death developed in 1220 patients (22.2%).

Admission HGL was a significant predictor of both IHD (7.6% vs. 4.2%, *p* \< 0.001) and 1-year death (26.2% vs. 21.3%, *p* = 0.001). DM was also a significant predictor of 1-year death (24.8% in DM vs. 20.5% in non-DM, *p* \< 0.001), but DM was not a predictor of IHD.

In subgroup analysis, admission HGL was a significant predictor of IHD in both DM and non-DM group. Admission HGL was also a significant predictor of 1-year death in non-DM group (27.8% vs. 19.9%, *p* = 0.003), but it was not a predictor of 1-year death in DM group ([Figure 2](#jcm-09-00149-f002){ref-type="fig"}). In Kaplan--Meier survival curve analysis, admission HGL was associated with significantly lower death free survival in non-DM group, but not in DM group ([Figure 3](#jcm-09-00149-f003){ref-type="fig"}). In multivariate analysis, admission HGL was an independent predictor of IHD regardless of the presence of DM ([Table 3](#jcm-09-00149-t003){ref-type="table"}), and admission HGL was also an independent predictor of 1-year mortality in non-DM patients ([Table 4](#jcm-09-00149-t004){ref-type="table"}).

3.4. Impacts of DM and Admission HGL on 1-Year Mortality According to HF Subtypes {#sec3dot4-jcm-09-00149}
---------------------------------------------------------------------------------

HFrEF was diagnosed in 3160 patients (59.7%), and HFpEF was diagnosed in 1269 patients (24.0%). HF with mid-range EF was diagnosed in 868 patients (16.3%).

In Kaplan--Meier survival curve analysis, death free survival of HFrEF with DM group was the worst among the four patients and the death-free survival of other three groups were not so different one another ([Figure 4](#jcm-09-00149-f004){ref-type="fig"}A).

In Kaplan--Meier survival curve analysis, death free survival was significantly worse in HFrEF patients with admission HGL than in HFrEF patients without admission HGL or HFpEF patients. HFpEF patients without admission HGL showed trend toward better death-free survival than those HFpEF with admission HGL or HFrEF without admission HGL. Death-free survival was quite similar between HFpEF patients with admission HGL and HFrEF patients without admission HGL ([Figure 4](#jcm-09-00149-f004){ref-type="fig"}B).

4. Discussion {#sec4-jcm-09-00149}
=============

Through a nation-wide registry study for AHF, we investigated the impact of admission HGL on IHD and 1-year mortality in patients with or without DM, and the present study demonstrated several clinically important findings. Firstly, admission HGL was a significant predictor of IHD and 1-year death, whereas DM was only a predictor of 1-year death in patients with AHF and DM was not a predictor of IHD. Secondly, admission HGL was an independent predictor of 1-year mortality in non-DM patients with AHF, but not in DM patients. Thirdly, death free survival was significantly worse in HFrEF patients with DM than in HFrEF patients without DM or HFpEF patients, and death free survival was significantly worse in HFrEF patients with admission HGL than in HFrEF patients without admission HGL or HFpEF patients. To the best of our knowledge, the present study is the largest study evaluating the usefulness or clinical significance of admission HGL on IHD or 1-year mortality in patients with AHF according to the types of HF. In addition to the presence of DM, simple evaluation of admission HGL would be useful in identifying high-risk group of AHF or in the risk stratification of AHF. Careful monitoring and intensive medical therapy should be considered in AHF patients with admission HGL, regardless of DM.

4.1. Admission HGL or DM and IHD {#sec4dot1-jcm-09-00149}
--------------------------------

In the present study, irrespective of DM, admission HGL was a significant predictor of IHD in AHF, but DM was not a predictor of IHD. Several studies also have shown that HGL is an independent predictor of IHD in patients with AHF \[[@B13-jcm-09-00149],[@B14-jcm-09-00149],[@B15-jcm-09-00149],[@B16-jcm-09-00149]\]. Sud et al. also showed that mildly elevated presentation blood glucose is associated with 30-day mortality and hospitalization in AHF patients with no pre-existing DM \[[@B16-jcm-09-00149]\]. Results from an international observation cohort showed that blood glucose concentrations at presentation are powerfully prognostic for 30-day mortality, independent of a diagnosis of DM \[[@B15-jcm-09-00149]\]. Likewise, it was reported that stress HGL with AMI is associated with an increased risk of IHD in patients with and without DM \[[@B3-jcm-09-00149]\]. Considering these results and our study, it is suggested that admission HGL is a simple but an important predictor of IHD in AHF. However, there are contradictory results regarding the impact of DM on IHD in patients with AHF. Some studies including large cohort study demonstrated that DM is an important predictor of IHD in AHF \[[@B17-jcm-09-00149],[@B18-jcm-09-00149]\]. However, as in the result of our study, DM was not a predictor of IHD in other studies; rather, DM was an important predictor of mortality after hospital discharge from AHF \[[@B8-jcm-09-00149],[@B19-jcm-09-00149]\]. Therefore, the issue regarding the impact of DM on IHD in patients with AHF should be clarified through further larger well-designed studies.

4.2. Admission HGL or DM and 1-Year Death {#sec4dot2-jcm-09-00149}
-----------------------------------------

Basically, a few of the literatures so far reported about long-term effect of admission HGL. However, some reported that long-term outcome was also affected. Kattel et al. showed that 1.8 year-mortality was higher in ADHF patients with higher admission glucose level \[[@B7-jcm-09-00149]\]. However, Aljohar et al. reported that HGL on admission is independently associated with hospital and short-term mortality in AHF patients \[[@B20-jcm-09-00149]\]. In the contrary, Kosiborod et al. reported that they found no significant association between admission glucose levels and mortality in a large cohort of 50,532 elderly patients hospitalized with heart failure \[[@B9-jcm-09-00149]\]. They said that outcomes seen in AMI cannot be readily applied to patients hospitalized with other cardiovascular conditions. Also, there were groups that reported that HGL in HF was a predictor of IHD but not of 1-year mortality \[[@B21-jcm-09-00149],[@B22-jcm-09-00149]\]. Some group presented no effect on both short- and long-term mortality \[[@B23-jcm-09-00149]\]. However, they performed a prospective study with relatively small subjects and used fasting glucose level, which is different from random admission glucose level. Despite of such a wide discrepancy between studies, however, the present study was unique in that hyperglycemic patients were divided into true diabetic and non-diabetic patients, showing that only non-diabetic patients with HGL had higher long-term mortality. Proposed mechanism is that HGL can increase cardiac contractility, which is only applied to patients with DM \[[@B24-jcm-09-00149]\]. The authors reported slightly prolonged walking distance in type 2 diabetic heart failure patients in the study.

4.3. HGL and Increased SNS Affecting HF Mortality {#sec4dot3-jcm-09-00149}
-------------------------------------------------

The SNS is associated with glucose homeostasis by inhibiting insulin secretion and increasing glucagon secretion \[[@B25-jcm-09-00149]\]. Therefore, HGL of non-DM patients may reflect stress state and increased SNS. However, HGL of DM patients is usually attributable to the poor glycemic control. There are reports that DM may be a strong independent predictor for HF. An animal study reported that DM causes metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to increased workload \[[@B26-jcm-09-00149]\]. Another study showed that advanced heart failure causes myocardial insulin resistance by decreasing myocardial ATP levels and GLUT-4 translocation \[[@B27-jcm-09-00149]\]. Consistent with that finding, there is growing evidence about myocardial insulin insensitivity in dilated cardiomyopathy (DCM). In heart failure patients with DCM, there is myocardial insulin insensitivity so that glucose is not used as fuel. In this situation, it is reported that HGL increases myocardial contractility \[[@B24-jcm-09-00149]\]. Admission HGL may be the response to danger and reflect of activated SNS. However, treatment for diabetes might have the patient overcome this insensitivity. That is the proposed mechanism why HGL of diabetic patients did not affect long-term mortality. This has been also demonstrated in some clinical studies.

4.4. Impacts of DM and Admission HGL on 1-Year Mortality According to HF Subtypes {#sec4dot4-jcm-09-00149}
---------------------------------------------------------------------------------

Usually, survival rate of HFpEF are better than that of HFrEF (*p* = 0.025 by log-rank test, [Figure S1](#app1-jcm-09-00149){ref-type="app"}). In the present study, however, HFpEF and HFrEF showed no differences in 1-year mortality without DM (19.2% vs. 20.0%, *p* = 0.619). Patients with HFrEF showed higher mortality than those with HFpEF only in the presence of DM (25.7% vs. 20.8%, *p* = 0.022) in our data. However, MacDonald et al. \[[@B28-jcm-09-00149]\]. showed that mortality benefit of HFpEF over HFrEF was maintained regardless of DM during the follow-up duration of 3.5 years. At 1-year follow-up, however, HFpEF with DM showed similar mortality with non-diabetic HFpEF, which is consistent with our study result. The mortality of non-diabetic HFrEF patients was higher than non-diabetic HFpEF patients, but this can be explained by dominant ischemic etiology of HFrEF in the study population.

There is paucity of data analyzing the impact of admission HGL according to HF subtypes. In the present study, HFpEF patients without HGL showed better survival than HFrEF patients with HGL (*p* \< 0.001). In addition, they showed trend toward better survival than HFrEF patients without HGL and HFpEF patients with HGL. This may be translated into worse survival in patients with HGL regardless of LVEF, although the discriminative effect was greater in HFrEF. Therefore, it seems that HGL associated with SNS activation at presentation influence the long-term clinical outcome of patients with AHF. Indeed, there is a study that investigated the effect of nebivolol on HF in patients with or without DM \[[@B29-jcm-09-00149]\]. The result showed that only non-DM group had benefit on primary outcome of all-cause mortality and cardiovascular hospitalization. Regulating SNS strategy such as adding beta-blockers in AHF patients with admission HGL might be warranted in future study.

5. Study Limitations {#sec5-jcm-09-00149}
====================

The present study has several limitations. First, as a prospective multicenter registry, not all variables that we want to analyze were collected. Second, there is no definite explanation for SNS activation and blood glucose except for proposed mechanism. However, this maybe hypothesis-generating at least. Third, rehospitalization rate was not analyzed in this study, since it was difficult to identify rehospitalization in the outside hospital. Therefore, the rehospitalization rate might not be precise. Fourth, there is no definite rule-out criteria using Hb A1c for patients with suspected DM. However, not all patients can undergo oral glucose tolerance test in the setting of AHF. Therefore, HbA1c could be a reasonable choice in this clinical situation. Finally, the 10 tertiary hospitals which participated in the present study might not be representative of the whole AHF population of Korea; however, as a relatively single-ethnicity country, 10 large-volume hospitals may represent the nation. There would be not too many differences.

6. Conclusions {#sec6-jcm-09-00149}
==============

Despite several potential limitations, the present study demonstrated that admission HGL, in addition to DM, is a simple and useful predictor of IHD and 1-year death in patients with AHF. Therefore, admission HGL can be useful in identifying high-risk group of AHF or in the risk stratification of AHF. Careful monitoring and intensive medical therapy for heart failure should be considered in AHF patients with admission HGL, regardless of the presence of DM. Further larger investigations to elucidate the actual mechanism for these results will be needed.

The following are available online at <https://www.mdpi.com/2077-0383/9/1/149/s1>, Table S1: Comparison of baseline characteristics between DM and non-DM. Figure S1: Comparison of death-free survival between patients with heart failure with preserved versus reduced ejection fraction. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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jcm-09-00149-t001_Table 1

###### 

Baseline characteristics.

  Variables                                     DM (*n* = 2125)                                         No DM (*n* = 3416)                                                           
  --------------------------------------------- --------------------------- --------------------------- -------------------- --------------------------- --------------------------- ---------
  Age (years)                                   70.8 ± 11.3                 70.2 ± 11.5                 0.223                72.9 ± 12.9                 67.0 ± 16.1                 \<0.001
  Male sex (%)                                  400 (50.1)                  757 (57.1)                  0.002                115 (46.4)                  1670 (52.7)                 0.054
  Body mass index (kg/m^2^)                     23.6 ± 3.6                  24.0 ± 4.0                  0.017                22.5 ± 3.3                  23.0 ± 3.9                  0.014
  Systolic blood pressure (mmHg)                138.1 ± 33.0                132.1 ± 29.3                \<0.001              139.0 ± 36.6                128.5 ± 29.1                \<0.001
  Diastolic blood pressure (mmHg)               79.9 ± 19.7                 78.1 ± 17.6                 0.035                82.3 ± 20.3                 78.2 ± 18.8                 0.003
  Heart rate (bpm)                              98.2 ± 26.9                 90.4 ± 23.9                 \<0.001              102.3 ± 28.8                91.5 ± 26.0                 \<0.001
  Hypertension                                  586 (73.3)                  985 (74.3)                  0.632                145 (58.5)                  1564 (49.4)                 0.006
  Heart failure history                         326 (40.8)                  660 (49.8)                  \<0.001              84 (33.9)                   1338 (42.2)                 0.010
  Dyslipidemia                                  645 (52.9)                  443 (59.8)                  0.003                97 (44.7)                   984 (34.7)                  0.003
  Smoking history                               304 (38.0)                  550 (41.5)                  0.118                99 (39.9)                   1187 (37.5)                 0.443
  Alcohol history                               278 (34.8)                  502 (37.9)                  0.156                78 (31.5)                   1264 (39.9)                 0.009
  Valvular heart disease                        72 (9.0)                    165 (12.4)                  0.015                21 (8.5)                    542 (17.1)                  \<0.001
  Cerebrovascular disease                       139 (17.4)                  253 (19.1)                  0.333                34 (13.7)                   414 (13.1)                  0.775
  Ischemic heart disease                        304 (38.0)                  535 (40.3)                  0.294                68 (27.4)                   654 (20.7)                  0.012
  Chronic kidney disease                        169 (21.2)                  302 (22.8)                  0.383                19 (7.7)                    304 (9.6)                   0.316
  Atrial fibrillation                           145 (18.1)                  392 (29.6)                  \<0.001              54 (21.8)                   941 (29.7)                  0.008
  Serum glucose (mg/dL)                         291.1 ± 87.3                137.1 ± 36.0                \<0.001              259.1 ± 61.2                120.8 ± 27.8                \<0.001
  Hb A1c (%)                                    8.0 ± 1.6                   6.9 ± 1.0                   \<0.001              5.8 ± 0.3                   5.8 ± 0.4                   0.764
  Serum creatinine (mg/dL)                      1.8 ± 1.6                   1.7 ± 1.6                   0.373                1.5 ± 1.4                   1.3 ± 1.4                   0.132
  Glomerular filtration rate (ml/min)           61.0 ± 36.1                 66.0 ± 39.9                 0.004                67.1 ± 33.7                 79.6 ± 40.0                 \<0.001
  High-sensitivity C-reactive protein\*         1.02 (0.26--3.71)           0.67 (0.23--2.24)           \<0.001              0.88 (0.24--2.41)           0.58 (0.18--2.00)           0.684
  Brain natriuretic peptide\*                   993.8 (617.3--1845.5)       893.3 (470.0--1685.8)       0.213                1004.4 (521.5--2120.0)      884.3 (447.1--1732.1)       0.188
  N-terminal Pro-B type natriuretic peptide\*   6198.3 (2441.5--15,835.3)   5365.0 (2344.0--13,443.0)   0.186                5983.0 (2361.0--13,833.0)   4497.0 (2031.0--10,416.0)   0.166
  Troponin-I\*                                  0.13 (0.05--1.20)           0.06 (0.03--0.21)           0.189                0.11 (0.05--0.76)           0.05 (0.03--0.19)           0.301

DM, diabetes mellitus; HGL, hyperglycemia. \* presented as median value (interquartile range).

jcm-09-00149-t002_Table 2

###### 

Echocardiographic findings.

  Variables           DM (*n* = 2125)                  No DM (*n* = 3416)                                 
  ------------------- ----------------- -------------- -------------------- -------------- -------------- ---------
  LVEDD (mm)          56.2 ± 8.9        57.9 ± 9.2     \<0.001              55.9 ± 9.7     57.5 ± 10.7    0.018
  LVESD (mm)          44.1 ± 11.0       45.8 ± 11.6    0.001                43.5 ± 11.3    45.1 ± 13.0    0.047
  LVEF (%)            36.8 ± 14.5       36.8 ± 15.1    0.996                37.0 ± 14.5    38.7 ± 16.1    0.081
  LA dimension (mm)   45.7 ± 8.3        48.7 ± 9.0     \<0.001              45.8 ± 10.6    48.7 ± 10.3    \<0.001
  E (m/s)             0.93 ± 0.35       0.96 ± 0.36    0.156                0.82 ± 0.33    0.95 ± 0.41    \<0.001
  DT (msec)           162.4 ± 59.5      167.5 ± 70.7   0.157                171.3 ± 69.7   172.1 ± 89.9   0.900
  E' (cm/s)           4.8 ± 3.4         4.7 ± 1.9      0.746                4.7 ± 1.9      5.2 ± 2.2      0.003
  S' (cm/s)           4.8 ± 1.8         5.1 ± 1.9      0.020                5.2 ± 2.0      5.1 ± 2.1      0.835
  E/E'                22.3 ± 11.0       22.8 ± 12.6    0.401                19.1 ± 8.5     20.5 ± 11.3    0.039
  SPAP (mmHg)         44.2 ± 14.6       45.2 ± 15.5    0.237                41.2 ± 14.3    43.5 ± 15.0    0.056

DM, diabetes mellitus; HGL, hyperglycemia; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LA, left atrium; E, early diastolic velocity of mitral inflow; DT, deceleration time of mitral inflow; E', early diastolic velocity of septal mitral annulus; S', systolic velocity of septal mitral annulus; RVSP, systolic pulmonary artery pressure.
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###### 

Independent predictors for in-hospital death in patients with and without diabetes mellitus

  Variables                                        DM (*n* = 2125)   Non-DM (*n* = 3416)                                 
  ------------------------------------------------ ----------------- --------------------- --------- ------ ------------ ---------
  Age \> 75 years                                  1.72              1.07--2.79            0.026     0.92   0.65--1.30   0.625
  Male sex                                         1.08              0.67--1.75            0.739     1.43   1.02--2.01   0.036
  History of hypertension                          0.98              0.59--1.62            0.927     0.94   0.67--1.33   0.740
  Systolic blood pressure \< 100 mmHg              3.59              2.17--5.93            \<0.001   2.88   2.06--4.05   \<0.001
  Renal insufficiency (initial GFR \< 60 mL/min)   1.70              1.05--2.76            0.030     2.14   1.53--2.99   \<0.001
  Admission hyperglycemia                          1.84              1.11--3.05            0.017     2.26   1.47--3.48   \<0.001
  Hb A1c                                           0.83              0.68--1.02            0.080                         
  Ischemic etiology                                1.88              1.16--3.04            0.010     1.91   1.37--2.68   0.74

DM, diabetes mellitus; CI, confidence interval; GFR, glomerular filtration rate.
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###### 

Independent predictors for 1-year death in patients without diabetes mellitus.

  Variables                                        Hazard Ratio   95% CI       *p*
  ------------------------------------------------ -------------- ------------ ---------
  Age \> 75 years                                  1.94           1.65--2.29   \<0.001
  Male sex                                         1.41           1.21--1.64   \<0.001
  Systolic blood pressure \< 100 mmHg              1.84           1.54--2.20   \<0.001
  Renal insufficiency (initial GFR \< 60 mL/min)   1.82           1.55--2.13   \<0.001
  Admission HGL                                    1.32           1.03--1.69   0.030
  No RAS inhibitors                                2.13           1.78--2.55   \<0.001

CI, confidence interval; GFR, glomerular filtration rate; HGL, hyperglycemia; RAS, renin-angiotensin system.
